Shots:
- The company reported the enrollment of the first participants in a P-I/II clinical study of its vaccine candidate- NVX‑CoV2373- developed utilizing nanoparticle technology. The vaccine includes Novavax’ Matrix‑M adjuvant to enhance immune responses and stimulate high levels of neutralizing Abs with its expected preliminary immunogenicity and safety results in Jul’2020
- The P-I-part evaluates the immunogenicity and safety of NVX‑CoV2373- both adjuvanted with Matrix‑M and unadjuvanted in ~130 healthy participants aged 18-59 yrs. at two sites in Australia. The study assesses two dose sizes (5 and 25 micrograms) with/out Matrix‑M
- The P-II part is expected to be conducted in multiple countries- including the US. The P-I/II approach allows the rapid advancement of NVX‑CoV2373 during the pandemic and is being supported by CEPI
Click here to read full press release/ article | Ref: Businesswire | Image: CNBC
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
